α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus
Tóm tắt
Newcastle disease virus (NDV) has been applied to oncolytic virotherapy for decades due to its naturally oncolytic property. In spite of the substantiation of the sialic acid receptors of NDV on host cells, knowledge of preference of sialic acid linkage in viral attachment and oncolytic effect is lacking and imperative to be elucidated. Surface plasmon resonance analysis and competitive inhibition with sialylated glycan receptor analogues were used to determine the affinity and the preference of sialic acid receptor. Treatments of sialyltransferase inhibitors and linkage-specific sialidases and transfection with sialyltransferase expression vector were performed to regulate sialic acids levels. We demonstrated that sialic acid was essential for NDV binding and infection of tumor cells. α2,6-linked sialic acid served as a high-affinity receptor for NDV and the ST6Gal I sialyltransferase that synthesizes α2-6 linkage of sialylated N-linked glycans in CHO-K1 cells promoted NDV binding and cytopathic effect. More importantly, an enhanced antitumor effect of NDV on aggressive SW620 colorectal carcinoma cells with high-level of cell surface α2,6-sialylation, but not SW480 cells with relative low-level of α2,6-sialylation, was observed both in vitro and in vivo. The study provides evidence of optimized therapeutic strategy in oncolytic virotherapy via partly defining α2,6-sialylated receptor as a “cellular marker” for NDV.
Tài liệu tham khảo
Alley WJ, Novotny MV (2010) Glycomic analysis of sialic acid linkages in glycans derived from blood serum glycoproteins. J Proteome Res 9:3062–3072. doi:10.1021/pr901210r
Bull C, Boltje TJ, van Dinther EA, Peters T, de Graaf AM, Leusen JH, Kreutz M, Figdor CG, den Brok MH, Adema GJ (2015) Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread. ACS Nano 9:733–745. doi:10.1021/nn5061964
Cassel WA, Garrett RE (1965) Newcastle disease virus as an antineoplastic agent. Cancer 18:863–868
Chen JY, Tang YA, Huang SM, Juan HF, Wu LW, Sun YC, Wang SC, Wu KW, Balraj G, Chang TT, Li WS, Cheng HC, Wang YC (2011) A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res 71:473–483. doi:10.1158/0008-5472.CAN-10-1303
Cheng X, Wang W, Xu Q, Harper J, Carroll D, Galinski MS, Suzich J, Jin H (2016) Genetic modification of oncolytic Newcastle disease virus for cancer therapy. J Virol 90:5343–5352. doi:10.1128/JVI.00136-16
Christie DR, Shaikh FM, Lucas JT, Lucas JR, Bellis SL (2008) ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res 1:3. doi:10.1186/1757-2215-1-3
Dall’Olio F, Chiricolo M (2001) Sialyltransferases in cancer. Glycoconj J 18:841–850
Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation–potential for therapeutics and diagnostics. Nat Rev Drug Discov 4:477–488. doi:10.1038/nrd1751
Elankumaran S, Rockemann D, Samal SK (2006) Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 80:7522–7534. doi:10.1128/JVI.00241-06
Ferreira L, Villar E, Munoz-Barroso I (2004) Gangliosides and N-glycoproteins function as Newcastle disease virus receptors. Int J Biochem Cell Biol 36:2344–2356. doi:10.1016/j.biocel.2004.05.011
Fuster MM, Esko JD (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5:526–542. doi:10.1038/nrc1649
Gessner P, Riedl S, Quentmaier A, Kemmner W (1993) Enhanced activity of CMP-neuAc: Gal beta 1–4GlcNAc:alpha 2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients. Cancer Lett 75:143–149
Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P (2001) The human sialyltransferase family. Biochimie 83:727–737
Harduin-Lepers A, Krzewinski-Recchi MA, Colomb F, Foulquier F, Groux-Degroote S, Delannoy P (2012) Sialyltransferases functions in cancers. Front Biosci (Elite Ed) 4:499–515
Hedlund M, Ng E, Varki A, Varki NM (2008) alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 68:388–394. doi:10.1158/0008-5472.CAN-07-1340
Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW, Stetler-Stevenson WG (2000) Validation of a model of colon cancer progression. J Pathol 192:446–454
Kim YJ, Varki A (1997) Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 14:569–576
Liu Z, Swindall AF, Kesterson RA, Schoeb TR, Bullard DC, Bellis SL (2011) ST6Gal-I regulates macrophage apoptosis via alpha2-6 sialylation of the TNFR1 death receptor. J Biol Chem 286:39654–39662. doi:10.1074/jbc.M111.276063
Mansour M, Palese P, Zamarin D (2011) Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol 85:6015–6023. doi:10.1128/JVI.01537-10
Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A, Almeida R, Silva F, Morais V, Costa J, Kihlberg J, Clausen H, Reis CA (2004) Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res 64:7050–7057. doi:10.1158/0008-5472.CAN-04-1921
Mayo M (2002) A summary of taxonomic changes recently approved by ICTV. Arch Virol 147:1655–1663. doi:10.1007/s007050200039
O’Shea LK, Abdulkhalek S, Allison S, Neufeld RJ, Szewczuk MR (2014) Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu(R)) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. Onco Targets Ther 7:117–134. doi:10.2147/OTT.S55344
Ozaki H, Matsuzaki H, Ando H, Kaji H, Nakanishi H, Ikehara Y, Narimatsu H (2012) Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin Exp Metastasis 29:229–238. doi:10.1007/s10585-011-9445-1
Patel MR, Kratzke RA (2013) Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res 161:355–364. doi:10.1016/j.trsl.2012.12.010
Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, Mandel U, Dell A, Pinder S, Taylor-Papadimitriou J, Burchell J (2010) Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology 20:1241–1250. doi:10.1093/glycob/cwq085
Sanchez-Felipe L, Villar E, Munoz-Barroso I (2012) alpha2-3- and alpha2-6- N-linked sialic acids allow efficient interaction of Newcastle disease virus with target cells. Glycoconj J 29:539–549. doi:10.1007/s10719-012-9431-0
Schauer R (2009) Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 19:507–514. doi:10.1016/j.sbi.2009.06.003
Schirrmacher V (2015) Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Expert Opin Biol Ther 15:1757–1771. doi:10.1517/14712598.2015.1088000
Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL (2005) Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res 65:4645–4652. doi:10.1158/0008-5472.CAN-04-3117
Sinkovics JG, Horvath JC (2000) Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16:1–15
Steenackers A, Vanbeselaere J, Cazet A, Bobowski M, Rombouts Y, Colomb F, Le Bourhis X, Guerardel Y, Delannoy P (2012) Accumulation of unusual gangliosides G(Q3) and G(P3) in breast cancer cells expressing the G(D3) synthase. Molecules 17:9559–9572. doi:10.3390/molecules17089559
Swindall AF, Bellis SL (2011) Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem 286:22982–22990. doi:10.1074/jbc.M110.211375
Swindall AF, Londono-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL (2013) ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Res 73:2368–2378. doi:10.1158/0008-5472.CAN-12-3424
Vasseur JA, Goetz JA, Alley WJ, Novotny MV (2012) Smoking and lung cancer-induced changes in N-glycosylation of blood serum proteins. Glycobiology 22:1684–1708. doi:10.1093/glycob/cws108
Villar E, Barroso IM (2006) Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview. Glycoconj J 23:5–17. doi:10.1007/s10719-006-5433-0
Wei D, Sun N, Nan G, Wang Y, Liu HQ, Peeters B, Chen ZN, Bian H (2012) Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Hum Gene Ther 23:700–710. doi:10.1089/hum.2011.207
Yogeeswaran G, Salk PL (1981) Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science 212:1514–1516
Zamarin D, Palese P (2012) Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 7:347–367. doi:10.2217/fmb.12.4